1	Epidemiologic Assessment of Pediatric Inflammatory Bowel Disease
2	Presentation in NYC During COVID-19
3	Janet Rosenbaum PhD <sup>1</sup> , Kenny Castro Ochoa MD <sup>2</sup> , Faria Hasan MD <sup>3</sup> , Alexa
4	Goldfarb DO <sup>4</sup> , Vivian Tang MD <sup>5</sup> , Gitit Tomer MD <sup>3</sup> , Thomas Wallach MD <sup>2</sup>
5	A 661. 4.
6	Affiliations:
7	<sup>1</sup> SUNY Downstate School of Public Health, Brooklyn, NY.
8	<sup>2</sup> SUNY Downstate Health Sciences University, Department of Pediatrics,
9	Division of Pediatric Gastroenterology, Brooklyn, NY.
10	<sup>3</sup> The Children's Hospital at Montefiore, Division of Pediatric
11	Gastroenterology Hepatology and Nutrition, Albert Einstein College of Medicine,
12	Bronx, NY.
13	<sup>4</sup> New York University, Department of Pediatrics, Division of Pediatric
	Gastroenterology, New York, NY.
14	<sup>5</sup> Maimonides Medical Center, Department of Pediatrics, Division of
15	Pediatric Gastroenterology, Brooklyn, NY.
16	rediatric Gastroenterology, Brooklyn, NT.
17	Address commendation for Themes Wells 1 MD Disision of Deliveria
18 10	Address correspondence to: Thomas Wallach MD, Division of Pediatric Gastroenterology, 450 Clarkson Ave, MSC 49. Brooklyn, NY, 11203.
19 20	
20 21	Fax: (718)270-198, Phone: (909)374-4350, Email: Thomas.wallach@downstate.edu
21	Short title: COVID-19 Impact on Pediatric IBD in NYC
22	Short the. COVID-19 impact on redatile IDD in NTC
23 24	Conflict of Interest Disclosures: The authors have no conflicts of
25	interest to report
26	
27	Funding/Support: No funding was secured for this study.
28	
29	Role of Funder/Sponsor (if any): none
30	
31	Abbreviations: Ulcerative Colitis (UC), Crohn's Disease (CD), Inflammatory
32	Bowel Disease (IBD), New York City (NYC).
33	• • • •
34	<b>Words:</b> 1886
35	
36	
37	

# 38 Contributors' Statement Page

39 40

Dr. Wallach conceptualized the study and organized the consortium of institutions.

41 Dr. Rosenbaum and Dr. Wallach designed the study, data collection instrument, and

42 analytical framework. Drs Castro Ochoa, Tang, Tomer, Hasan, and Goldfarb collected data,

43 organized local IRB approval at their respective institutions, and edited the manuscript. Dr.

44 Rosenbaum harmonized, cleaned, and analyzed the data. Dr. Castro Ochoa, Dr.

45 Rosenbaum, and Dr. Wallach wrote the manuscript. All authors reviewed, revised, and

46 approved the final manuscript as submitted and agree to be accountable for all aspects of

- 47 the work.
- 48

49

### 50 Abstract:

SARS-nCoV2 may have increased capacity to generate autoimmune disease; multiple 51 reports suggest increased risk of Type 1 Diabetes, and case reports suggest other 52 autoimmune linkages. Inflammatory Bowel Disease (IBD) pathogenesis appears to be a 53 54 mix of genetic susceptibility, microbial populations, and immune triggers such as infections. Given the perceived role of infection in pathogenesis, decreased incidence of all 55 infections during the pandemic secondary to non-pharmaceutical interventions should 56 decrease IBD incidence rates. The aim of this study was to evaluate the association 57 between the Covid-19 pandemic and IBD presentation in NYC using data from new 58 diagnoses at a consortium of institutions. 59 Using EMR systems all diagnoses at 4 collaborating institutions were retrieved from 2015-60 2021. We fit time series model (ARIMA) to the quarterly number of cases of each disease 61 for January 2016-March 2020 and forecast the subsequent 21 months. We not only did not 62 observe a decline in pediatric IBD secondary to absent viral illness but noted a statistically 63 significant increase in Crohn's Disease approximately 6 months after the initial 2020 64 COVID wave in NYC, and trends suggesting increases overall in IBD diagnoses above the 65 66 existing trend towards increased disease presentation that pre-dated the pandemic. This data suggests that there may be a linkage between SARS-nCoV2 infection rates and 67 68 subsequent pediatric IBD presentation, warranting further evaluation in the aftermath of the 69 Omicron wave.

70

### 71 Introduction

The SARS-nCoV2 pandemic has created multiple challenges, but emerging data 72 suggests additional possible long-term complications in the form of increased presentation 73 74 of autoimmune diseases. Multiple Analytic studies have demonstrated Type 1 Diabetes 75 diagnoses linked with SARS-nCov2 emergence, and case series suggest other autoimmune 76 linkages<sup>1-3</sup>. Inflammatory Bowel Disease (IBD) is an autoimmune condition typically presenting in late childhood and young adulthood, with pathogenesis thought to be a mix 77 of genetic susceptibility, microbial populations, and immune triggers such as infections<sup>4</sup>. 78 79 Given the hypothesized role of infection in pathogenesis, decreased incidence of all infections during the pandemic secondary to non-pharmaceutical interventions (NPI) 80 would likely be expected to generate a decrease in IBD incidence<sup>4, 5</sup>. As the first US locus 81 of a major SARS-nCoV2 outbreak, New York City represents a unique opportunity to 82 identify any signal of altered IBD presentation secondary to infection and the NPI 83

84 implemented to manage the pandemic. This study will evaluate any association between

the Covid-19 pandemic and new IBD diagnoses in NYC using data from a consortium ofinstitutions.

87

## 88 <u>Methods</u>

#### 89 Data

After institutional review board approval of respective institutions, we extracted date of diagnosis for Crohn's Disease (CD) (n=349) and Ulcerative Colitis (UC) (n=145) patients presenting in pediatric GI clinic diagnosed 2016-2021 from electronic health records (EHRs).

94 Measures

95 Date of diagnosis was coded as year and month of diagnosis with the day removed 96 for identifiability reasons. We measured the following demographic variables: year and 97 month of birth and EHR-recorded sex (always or almost always sex assigned at birth). Age 98 at diagnosis was measured in years; was at median 14.0 years (range 2-21 years) and was 99 available for all patients. For two institutions, we were able to extract race, ethnicity, and 100 zip code. Gender was a free entry field, and only male and female patients were present in 101 the data; 44.0% were female and 56.0% were male.

Race and ethnicity were measured by a free-entry field, and race was available for 102 30% of the participants and ethnicity for 44% of participants. Race was coded as White for 103 104 free entry fields of White, and coded Black for free entry fields including Black, African American, and the typographical error "Afriac-American" [sic]. Race was coded as 105 missing for declined, unavailable, or blank. Ethnicity was coded as Hispanic for free entry 106 fields including Dominican, Mexican, Hispanic, Latino unspecified, Chicano/a, Puerto 107 Rican, Salvadoran, South American, Spaniard, and Spanish. Participant ethnicity was coded 108 109 as missing for entries of Declined, blanks, not applicable, not known, unknown n/a, unavailable. 110

An individual-level association between covid-19 infection and IBD would give the strongest inference, so we gathered data about past Covid-19 infection, measured as EMR record of either a positive-Covid-19 antibody test or positive Covid-19 PCR test. However, only one patient tested positive for antibodies and only one patient tested positive by PCR, so these measures were not used. Children were under-tested (cite) and tests may not appear in their EHR where they received IBD diagnosis because they may have been tested at school, public hospital system, urgent care clinics, or health systems that do not

118 contribute to these EHR systems.

110	
119	
120	Analysis
121	Due to potentially different seasonal variation and time to presentation, we
122	analyzed CD and UC separately and excluded 22 cases of indeterminate IBD.
123	Using April 2020 as the first month of the covid-19 pandemic, we compared pre-
124	pandemic versus pandemic periods with the Pearson chi-square test and pairwise
125	proportion tests with Holm's correction. We fit an autoregressive integrated moving
126	average model (ARIMA) to the quarterly number of cases of each disease for January
127	2016-March 2020 and forecast the subsequent 21 months (April 2020-December 2021)
128	with 80% and 95% prediction intervals using the forecast library. <sup>5</sup> The model for
129	ulcerative colitis was ARIMA(1,0,0) with a mean of 1.91 cases per month (se=0.28), lag-1
130	autocorrelation (AR1) of 0.30 (se=0.13), residual standard deviation of 2.00. The forecast
131	varied only slightly across the interval. For ulcerative colitis, beginning in August 2020 an
132	average of 1.90 cases were forecast with $80\%$ prediction interval (0.00, 3.80) and $95\%$
133	prediction interval (-1.00, 4.81).
134	The model for Crohn's disease was $ARIMA(0,0,0)$ (white noise) with mean of 4.65
135	cases per month (se = $0.37$ ) and residual standard deviation of 7.07. Mean absolute scaled
136	error is less than 1, which means the model is better than the naïve model (repeating
137	previous year.) The forecast was uniform across the interval because the number of
138	Crohn's disease cases per month were white noise. For Crohn's disease, an average of
139	4.65 cases was forecast with 80% prediction interval (1.24, 8.06) and 95% prediction
140	interval (-0.57, 9.86).
141	We evaluated the robustness of results to monthly versus quarterly time period and
142	in a larger year span, using 2011-2021 data from 3 contributing institutions (Appendix).
143	To show seasonal patterns in diagnoses, we plotted total cases by month with loess
144	regression and 95% confidence intervals using ggplot2 stratified by pandemic versus pre-
145	pandemic diagnosis. <sup>6</sup> Residual plots showed no substantial departures from normality or
146	evidence of heteroskedasticity. The Durbin-Watson statistic showed no evidence of
147	autocorrelation for Crohn's disease for either period or for Ulcerative Colitis for the
148	SARS-nCoV2 pandemic period.
149	Results
150	Patients diagnosed during the pandemic did not differ in demographic

151 characteristics from patients diagnosed before the pandemic (Table 1). Downstate had a

larger share of cases during the pandemic (9.6% of cases at the 4 institutions) than before
the pandemic (4.3% of cases) and Maimonides had a smaller share of cases during the
pandemic (10.2% of cases) than before the pandemic (17.5% of cases) (p=0.03); there
were no significant differences between other institutions. Gender, age at diagnosis,
diagnosis, county of residence, race, and ethnicity did not differ pre-pandemic versus postpandemic.

We noted more CD diagnoses than expected in June and July during the pandemic compared with before the pandemic in the loess plots [Figure 1].

We noted more CD cases than forecast in the third quarter of 2020, which had 26 cases compared with upper limit of 95% prediction interval of 23.0 in ARIMA analysis **[Figure 2]**. We notice a trend towards elevation in UC diagnoses over time. Robustness checks using monthly data demonstrated similar rates exceeding 95% prediction in CD (July and September of 2020) and for UC in May and October of 2021, consistent with an elevation of mean monthly diagnoses.

166 As a first robustness check, we repeated the model with monthly data (2016-2021) [Figure 3]. The model for monthly ulcerative colitis was ARIMA (1,0,0) with a mean of 167 168 1.91 cases per month (se=0.28), lag-1 autocorrelation (AR1) of 0.30 (se=0.13), residual standard deviation of 2.00. The forecast varied only slightly across the interval. For 169 170 ulcerative colitis, beginning in August 2020 an average of 1.90 cases were forecast with 80% prediction interval (0.00, 3.80) and 95% prediction interval (-1.00, 4.81). The model 171 172 for Crohn's disease was ARIMA (0,0,0) (white noise) with mean of 4.65 cases per month (se = 0.37) and residual standard deviation of 7.07. Mean absolute scaled error is less than 173 1, which means the model is better than the naïve model (repeating previous year.) The 174 175 forecast was uniform across the interval because the number of Crohn's disease cases per month were white noise. For Crohn's disease, an average of 4.65 cases was forecast with 176 80% prediction interval (1.24, 8.06) and 95% prediction interval (-0.57, 9.86). We notice 177 more ulcerative colitis cases than forecast in May 2021 and October 2021, which had 5 178 cases each compared with upper limit of 95% prediction interval 4.81, and more Crohn's 179 disease cases than forecast in July 2020 (12 cases), September 2020 (10 cases), compared 180 181 with upper limit of 95% prediction interval 9.86.

As a second robustness check, we repeated the model with monthly and quarterly data from 2011-2021, which were available for 3 of the 4 institutions. **Table 2** compares the demographic data for these 3 institutions: as before, we notice that Downstate had more cases than usual during the pandemic than before the pandemic, and Maimonides

had fewer, but there were no other differences; these three institutions do not reportHispanic ethnicity.

The pre-pandemic model for quarterly ulcerative colitis was ARIMA(0,0,0) **[Figure 4]** with a mean of 2.81 cases per quarter (se = 0.28) and residual standard deviation of 2.88. The pre-pandemic model for quarterly Crohn's disease was ARIMA(0,0,0) with a mean of 7.22 cases per quarter (se = 0.54) and residual standard deviation of 11.2. Mean absolute scaled error for the pandemic data for UC and CD were 0.92 and 0.82, which are less than 1, which mean the models are better than the naïve model (repeating previous year.)

With these three institutions, we notice more Crohn's disease than forecast in the third quarter of 2020 which had 14 cases compared with upper limit of 95% prediction interval of 13.8, and more ulcerative colitis than forecast in the fourth quarter of 2021, which had 8 cases compared with upper limit of 95% prediction interval of 6.1. We notice a trend towards elevation in UC diagnoses over time.

### 200 Discussion

Decreases in viral infection did not decrease CD and UC presentation rates, suggesting either diminished importance of viral infection as a pathogenic trigger of IBD or a strong capacity for SARS-nCoV2 to drive IBD pathogenesis. Second, we observe a significant increase in CD diagnoses with a possible temporal linkage of 4-6 months after pre-omicron peak SARS-nCoV2 infection in NYC in March/April 2020.

Our study has several limitations. IBD does not present with consistent patterns, resulting in wide variability in data. The 4-6 month lag between the city's peak infection rate and CD is more consistent with a SARS-nCoV2 infection pathogenesis than with delayed presentation from cases during the lockdown period. Our data does not include all pediatric gastroenterology groups in NYC, which may create effects due to variations in patient choice of providers.

Our study suggests a risk that large increases of SARS-nCoV2 infection in pediatric patients may drive increases in IBD diagnoses, in particular CD. Given recent widespread infection during the omicron wave, this study highlights the necessity of follow-up investigation of changes in incidence using existing data infrastructure.

## Acknowledgments

We would like to acknowledge the contributions of the following individuals, Dalia Arostegui MD, Chika Oragui MD, Agata Mann MD, Jon Dooley MD, and Dr. Melanie Greifer MD who assisted in data collection, and Steven Schwarz MD who assisted in building our data gathering collaboration.

# References

- 1. Gottesman BL, Yu J, Tanaka C, et al. Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic. JAMA Pediatrics 2022.
- 2. Saad MA, Alfishawy M, Nassar M, et al. COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases. Curr Rheumatol Rev 2021;17:193-204.
- Barrett CE KA, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021. Volume 71. MMWR Morb Mortal Wkly Rep, 2022:59-65.
- 4. Sun L, Nava GM, Stappenbeck TS. Host genetic susceptibility, dysbiosis, and viral triggers in inflammatory bowel disease. Curr Opin Gastroenterol 2011;27:321-7.
- 5. Sullivan SG, Carlson S, Cheng AC, et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Euro Surveill 2020;25.

**Figure 1. Loess plots of UC and CD presentation by month.** A) Seasonal Loess plot of Ulcerative Colitis presentation by calendar month including all datapoints from 2016-2021. B) Seasonal Loess plot of Crohn's Disease presentation by calendar month including all datapoints from 2016-2021



**Figure 2. Time series (ARIMA) of UC and CD.** A) ARIMA time series analysis of UC presentation by 3 month period from 2016-2021 with 80% and 95% prediction intervals. B) ARIMA time series analysis of CD presentation by 3 month period from 2016-2021 with 80% and 95% prediction intervals.





Crohn's disease: 80% prediction interval (dark), 95% prediction interval (light)



Figure 4: Time series with prediction intervals (PI) forecast: quarterly ulcerative colitis (UC) and Crohn's disease (CD) cases, 2011-2021.



Figure 5: Time series with prediction intervals (PI) forecast for 3 institutions: monthly ulcerative colitis (UC) and Crohn's disease (CD) cases.





	All participants	Jan. 2016 – Mar. 2020	April 2020 – Dec. 2021	P-value
N	516	349	167	
Gender				0.6
Male	295 (57.2%)	196 (56.2%)	99 (59.3%)	
Female	221 (42.8%)	153 (43.8%)	67 (40.7%)	
Age at diagnosis				0.8
0-4	19 (3.7%)	13 (3.7%)	6 (3.6%)	
5-12	164 (31.8%)	114 (32.7%)	50 (29.9%)	
13-17	266 (51.6%)	180 (51.6%)	86 (51.5%)	
18-21	67 (13.0%)	42 (12.0%)	25 (15.0%)	
Institution		12 (12:070)	25 (15.676)	0.02
Downstate	31 (6.0%)	15 (4.3%)	16 (9.6%)	0.02
Maimonides	78 (15.1%)	61 (17.5%)	17 (10.2%)	-
Montefiore	236 (45.7%)	155 (44.4%)	81 (48.5%)	
NYU	171 (33.1%)	118 (33.8%)	53 (31.7%)	
	1/1 (33.1%)	110 (33.0%)	JJ (J1.1 /0)	0.6
Race	106 (20 59/)	76 (21 80/)	20 (19 0%)	0.6
White	106 (20.5%)	76 (21.8%)	30 (18.0%)	
Black	45 (8.7%)	29 (8.3%)	16 (9.6%)	
Other or not reported	365 (70.7%)	244 (69.9%)	121 (72.5%)	
Hispanic ethnicity				0.6
Not Hispanic	121 (23.4%)	83 (23.8%)	38 (22.9%)	
Hispanic	110 (21.3%)	70 (20.1%)	40 (24.0%)	
Not reported	285 (55.2%)	196 (56.2%)	89 (53.3%)	
Year of diagnosis				n.a.
2016	67 (13.0%)	67 (19.2%)	0 (0%)	
2017	84 (16.3%)	84 (24.1%)	0 (0%)	
2018	80 (15.5%)	80 (22.9%)	0 (0%)	
2019	90 (17.4%)	90 (25.7%)	0 (0%)	
2020	96 (18.6%)	28 (8.0%)	68 (40.7%)	
2021	99 (19.2%)	0 (0%)	99 (59.3%)	
Diagnosis				0.7
Crohn's Disease	349 (67.6%)	237 (67.9%)	112 (67.1%)	
Ulcerative Colitis	145 (28.1%)	98 (28.1%)	47 (28.1%)	
Undetermined	20 (3.9%)	12 (3.4%)	8 (4.8%)	
Not reported	2 (0.4%)	2 (0.6%)	0 (0%)	
Location	, ,	, ,		0.4
Manhattan	31 (6.0%)	20 (5.7%)	11 (6.6%)	
Brooklyn	206 (39.9%)	148 (42.4%)	58 (34.7%)	
Queens	21 (4.1%)	12 (3.4%)	9 (5.4%)	_
Bronx	151 (29.3%)	100 (28.6%)	51 (30.5%)	
Staten Island	11 (2.1%)	6 (1.7%)	5 (3.0%)	
Westchester	42 (8.1%)	28 (8.0%)	14 (8.4%)	
Rockland	30 (5.8%)	18 (5.2%)	12 (7.2%)	
Long Island	11 (2.1%)	10 (2.9%)	1 (0.6%)	
Other NY or PA or CT or NJ	5 (1.0%)	2 (0.6%)	3 (1.8%)	
Not reported	8 (1.6%)	5 (1.4%)	3 (1.8%)	

Table 1: Demographics of participants (2016-2021): All percentages are column percentages. 90

P-value from chi-square test of association between time period (pre-pandemic versus pandemic) and each variable.

	All participants	Jan. 2011 – Mar. 2020	April 2020 – Dec. 2021	P-value
Ν	466	380	86	
Gender				0.6
Male	258 (55.4%)	208 (54.7%)	50 (58.1%)	
Female	208 (44.6%)	172 (45.3%)	36 (41.9%)	
Age at diagnosis				0.6
0-4	6 (1.3%)	4 (1.1%)	2 (2.3%)	
5-12	166 (35.6%)	137 (36.1%)	29 (33.7%)	
13-17	258 (55/4%)	212 (55.8%)	46 (53.5%)	
18-21	36 (7.7%)	27 (7.1%)	9 (10.5%)	
Institution				0.004
Downstate	42 (9.0%)	26 (6.8%)	16 (18.6%)	
Maimonides	110 (23.6%)	93 (24.5%)	17 (19.8%)	
NYU	314 (67.4%)	261 (68.7%)	53 (61.6%)	
Race				0.4
White	84 (20.5%)	70 (18.4%)	14 (16.3%)	
Black	7 (8.7%)	7 (1.8%)	0	
Other or not reported	375 (70.7%)	303 (79.7%)	72 (83.7%)	
Hispanic ethnicity				n.a.
Not Hispanic	0	0	0	
Hispanic	31 (6.7%)	23 (6.1%)	8 (9.3%)	
Not reported	435 (93.3%)	357 (93.9%)	78 (90.7%)	
Year of diagnosis	400 (00.070)	337 (33.376)	///////////////////////////////////////	n.a.
2011	33 (7.1%)	33 (8.7%)	0 (0%)	11.0.
2012	27 (5.8%)	27 (7.1%)	0 (0%)	
2012	34 (7.3%)	34 (8.9%)	0 (0%)	
2013	36 (7.7%)	36 (9.5%)	0 (0%)	
2014	56 (12.0%)	56 (14.7%)	0 (0%)	
2015	39 (8.4%)	39 (10.3%)	0 (0%)	
2010	45 (9.7%)	45 (11.8%)	0 (0%)	
2017	43 (9.2%)	43 (11.3%)	0 (0%)	
2018	53 (11.4%)	53 (13.9%)	0 (0%)	
2019	50 (10.7%)	14 (3.7%)	36 (41.9%)	
2020	50 (10.7%)	0 (0%)	50 (58.1%)	
	50 (10.7%)	0 (0%)	30 (38.1%)	0.3
Diagnosis Crohn's Disease	327 (70.2%)	267 (70.3%)	60 (69.8%)	0.3
Ulcerative Colitis	126 (27.0%)	104 (27.4%)	22 (25.6%)	
Undetermined	. ,			
	10 (2.1%)	6 (1.6%)	4 (4.7%)	
Not reported	3 (0.6%)	3 (0.8%)	0 (0%)	0.2
Location Manhattan	40 (10 59/)	28 (10.0%)	11 (12 00/)	0.2
Manhattan	49 (10.5%)	38 (10.0%) 257 (67.6%)	11 (12.8%)	
Brooklyn	313 (67.2%)		56 (65.1%)	
Queens	31 (6.7%)	23 (6.1%)	8 (9.3%)	
Bronx Staten Island	6 (1.3%)	4 (1.1%)	2 (2.3%)	
Staten Island	13 (2.8%)	9 (2.4%)	4 (4.7%)	
Westchester	4 (0.9%)	4 (1.1%)	0	
Rockland	14 (3.0%)	10 (2.6%)	4 (4.7%)	
Long Island	24 (5.2%)	23 (6.1%)	1 (1.2%)	
Other NY or PA or CT or NJ	5 (1.1%)	5 (1.3%)	0	
Not reported	7 (1.5%)	7 (1.8%)	0	

#### Table 2: Demographics of participants at 3 institutions, 2011-2021

P-value from chi-square test of association between each variable and pre-pandemic versus postpandemic with simulated p-value.